Patents by Inventor Hreinn Stefansson
Hreinn Stefansson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110111419Abstract: The present invention relates to genomic copy number variations as risk factors for schizophrenia. The invention provides methods and kits for risk management of schizophrenia, by assessing such copy number variations in the genome of individuals.Type: ApplicationFiled: July 3, 2009Publication date: May 12, 2011Applicant: deCODE Geneties ehf.Inventors: Hreinn Stefansson, Andres Ingason
-
Publication number: 20100047807Abstract: The present inventions discloses genetic markers and haplotypes that have been found to be associated with risk of Restless Legs Syndrome (RLS), Periodic Limb Movement Disorder (PLMD), and Periodic Limb Movements of Sleep (PLMS). Methods for determination of susceptibility of these disorders are disclosed using such markers, as are kits useful in such determination.Type: ApplicationFiled: April 11, 2008Publication date: February 25, 2010Applicant: deCODE Genetics ehf.Inventors: Hreinn Stefansson, Hjorvar Petursson
-
Patent number: 7495147Abstract: Nucleic acids comprising the neuregulin 1 gene (NRG1) and encoding NRG1 polypeptides are disclosed. Also described are related nucleic acids encoding NRG1 polypeptides; NRG1 polypeptides; antibodies that bind to NRG1 polypeptides; methods of diagnosis of susceptibility to schizophrenia; assays for agents that alter the activity of NRG1 polypeptide or which identify NRG1 binding agents, and the gents or binding agents identified by the assays; NRG1 therapeutic agents, including the NRG1 nucleic acids, NRG1 polypeptides, or agents that alter the activity of an NRG1 polypeptides; pharmaceutical compositions comprising the NRG1 therapeutic agents; as well as methods of therapy of schizophrenia. Novel haplotypes with a common core haplotype in affected individuals are described, as well as their use in methods for screening for susceptibility to schizophrenia.Type: GrantFiled: March 26, 2002Date of Patent: February 24, 2009Assignee: deCODE genetics ehf.Inventors: Hreinn Stefansson, Valgerdur Steinthorsdottir, Jeffrey R. Gulcher, Mark Gurney, Thorkell Andresson
-
Publication number: 20080263690Abstract: Nucleic acids comprising the neuregulin 1 gene (NRG1) and encoding NRG1 polypeptides are disclosed. Also described are related nucleic acids encoding NRG1 polypeptides; NRG1 polypeptides; antibodies that bind to NRG1 polypeptides; methods of diagnosis of susceptibility to schizophrenia; assays for agents that alter the activity of NRG1 polypeptide or which identify NRG1 binding agents, and the agents or binding agents identified by the assays; NRG1 therapeutic agents, including the NRG1 nucleic acids, NRG1 polypeptides, or agents that alter the activity of an NRG1 polypeptides; pharmaceutical compositions comprising the NRG1 therapeutic agents; as well as methods of therapy of schizophrenia. Novel haplotypes with a common core haplotype in affected individuals are described, as well as their use in methods for screening for susceptibility to schizophrenia.Type: ApplicationFiled: March 26, 2002Publication date: October 23, 2008Inventors: Hreinn Stefansson, Valgerdur Steinthorsdottir, Jeffrey R. Gulcher, Mark Gurney, Thorkell Andresson
-
Publication number: 20050208527Abstract: Nucleic acids comprising the neuregulin 1 gene (NRG1) and encoding NRG1 polypeptides are disclosed. Also described are related nucleic acids encoding NRG1 polypeptides; NRG1 polypeptides; antibodies that bind to NRG1 polypeptides; methods of diagnosis of susceptibility to schizophrenia; assays for agents that alter the activity of NRG1 polypeptide or which identify NRG1 binding agents, and the agents or binding agents identified by the assays; NRG1 therapeutic agents, including the NRG1 nucleic acids, NRG1 polypeptides, or agents that alter the activity of an NRG1 polypeptides; pharmaceutical compositions comprising the NRG1 therapeutic agents; as well as methods of therapy of schizophrenia. Novel haplotypes with a common core haplotype in affected individuals are described, as well as their use in methods for screening for susceptibility to schizophrenia.Type: ApplicationFiled: November 22, 2004Publication date: September 22, 2005Applicant: deCODE genetics ehf.Inventors: Hreinn Stefansson, Valgerdur Steinthorsdottir, Jeffrey Gulcher, Mark Gurney, Thorkell Andresson
-
Publication number: 20020165144Abstract: Nucleic acids comprising the neuregulin 1 gene (NRG1) and encoding NRG1 polypeptides are disclosed. Also described are related nucleic acids encoding NRG1 polypeptides; NRG1 polypeptides; antibodies that bind to NRG1 polypeptides; methods of diagnosis of susceptibility to schizophrenia; assays for agents that alter the activity of NRG1 polypeptide or which identify NRG1 binding agents, and the agents or binding agents identified by the assays; NRG1 therapeutic agents, including the NRG1 nucleic acids, NRG1 polypeptides, or agents that alter the activity of an NRG1 polypeptides; pharmaceutical compositions comprising the NRG1 therapeutic agents; as well as methods of therapy of schizophrenia.Type: ApplicationFiled: September 5, 2001Publication date: November 7, 2002Applicant: deCODE genetics ehf, ICELANDInventors: Hreinn Stefansson, Valgerdur Steinthorsdottir, Jeffrey R. Gulcher, Mark Gurney, Thorkell Andresson
-
Publication number: 20020094954Abstract: Nucleic acids comprising the neuregulin-1-associated gene 1 (NRG1AG1) and encoding NRG1AG1 polypeptides are disclosed. Also described are related nucleic acids encoding NRG1AG1 polypeptides; NRG1AG1 polypeptides; antibodies that bind to NRG1AG1 polypeptides; methods of diagnosis of susceptibility to schizophrenia; assays for agents that alter the activity of NRG1AG1 polypeptide or which identify NRG1AG1 binding agents, and the agents or binding agents identified by the assays; NRG1AG1 therapeutic agents, including the NRG1AG1 nucleic acids, NRG1AG1 polypeptides, or agents that alter the activity of an NRG1AG1 polypeptides; pharmaceutical compositions comprising the NRG1AG1 therapeutic agents; as well as methods of therapy of schizophrenia.Type: ApplicationFiled: February 28, 2001Publication date: July 18, 2002Applicant: deCODE genetics, ehf,Inventors: Hreinn Stefansson, Valgerdur Steinthorsdottir, Jeffrey R. Gulcher
-
Publication number: 20020045577Abstract: Nucleic acids comprising the neuregulin 1 gene (NRG1) and encoding NRG1 polypeptides are disclosed. Also described are related nucleic acids encoding NRG1 polypeptides; NRG1 polypeptides; antibodies that bind to NRG1 polypeptides; methods of diagnosis of susceptibility to schizophrenia; assays for agents that alter the activity of NRG1 polypeptide or which identify NRG1 binding agents, and the agents or binding agents identified by the assays; NRG1 therapeutic agents, including the NRG1 nucleic acids, NRG1 polypeptides, or agents that alter the activity of an NRG1 polypeptides; pharmaceutical compositions comprising the NRG1 therapeutic agents; as well as methods of therapy of schizophrenia.Type: ApplicationFiled: February 28, 2001Publication date: April 18, 2002Applicant: deCODE geneticsInventors: Hreinn Stefansson, Valgerdur Steinthorsdottir, Jeffery R. Gulcher